annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 3G Incidence and risk factors for biliary sclerosis following adjuvant hepatic
arterial infusion with floxuridine after hepatectomy for metastatic colorectal
cancer. (Abstract #3556)
K. Ito, H. Ito, N. E. Kemeny, M. Gonen, P. Allen, Y. Fong, R. P. DeMatteo,
L. H. Blumgart, W. R. Jarnagin, M. I. D’Angelica
Brd. 3H A randomized phase II trial of adjuvant hepatic arterial infusion and systemic
chemotherapy with or without bevacizumab in patients with resected hepatic
metastases from colorectal cancer. (Abstract #3557)
N. E. Kemeny, W. R. Jarnagin, M. Capanu, Y. Fong, A. Gewirtz, R. P. DeMatteo,
M. I. D’Angelica
Brd. 4A Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil
(FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable
colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study.
(Abstract #3558)
D. Malka, E. Paris, C. Caramella, E. Boucher, R. Guimbaud, A. Celebic,
T. De Baere, D. Elias, J. Pignon, M. Ducreux
Brd. 4B Unexpected increased biliary toxicity when systemic bevacizumab is added
to hepatic arterial infusion. (Abstract #3559)
D. G. Power, M. Capanu, D. Patel, A. Gewirtz, W. R. Jarnagin, Y. Fong,
M. I. D’Angelica, R. P. DeMatteo, N. E. Kemeny
Brd. 4C Feasibility of neoadjuvant transarterial chemoembolization (TACE) using
irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable
colorectal liver metastases (RCLM): A phase II study. (Abstract #3560)
G. J. Poston, E. O’Grady, H. Z. Malik, S. W. Fenwick, M. Terlizzo, C. Byrne,
M. Rees, J. Figueras, R. Adam
Brd. 4D Premedication and incidence of infusion-related reactions in patients with
metastatic colorectal cancer treated with cetuximab plus irinotecan-based
chemotherapy. (Abstract #3561)
H. Wilke, S. Siena, A. H. Loos, K. Berghoff, C. Kohne, E. Van Cutsem
Brd. 4E Use of germ-line polymorphisms in genes involved in the IGF pathway to
predict efficacy of cetuximab independent of K-ras in mCRC patients
(IMCL-0144). (Abstract #3562)
T. Winder, W. Zhang, D. Yang, Y. Ning, P. O. Bohanes, S. Hu-Lieskovan,
D. J. Mauro, C. Langer, E. K. Rowinsky, H. Lenz
Brd. 4F Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in
advanced rectal cancer. (Abstract #3563)
D. Vallbohmer, P. P. Grimminger, D. Yang, K. D. Danenberg, P. Danenberg,
D. Arnold, J. H. Machiels, C. Roedel, V. Velenik, H. Lenz
Brd. 4G Early magnesium modifications as a surrogate markers of efficacy of
cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer
patients. (Abstract #3564)
B. Vincenzi, D. Santini, S. Galluzzo, F. Loupakis, P. Correale, R. Addeo,
S. Del Prete, A. Falcone, G. Francini, G. Tonini
Brd. 4H Randomized phase III study of panitumumab (pmab) with FOLFIRI versus
FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic
colorectal cancer (mCRC): Analysis by tumor epidermal growth factor
receptor (EGFR) staining. (Abstract #3565^)
M. Peeters, A. Cervantes-Ruiperez, A. Strickland, T. Ciuleanu, P. N. Mainwaring,
V. I. Tzekova, A. Santoro, C. W. Johnson, A. Zhang, J. L. Gansert
Brd. 5A Randomized phase III study of panitumumab (pmab) with FOLFOX4
compared to FOLFOX4 alone as first-line treatment (tx) for metastatic
colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor
receptor (EGFR) tumor staining. (Abstract #3566^)
S. Siena, J. Tabernero, D. Cunningham, P. Koralewski, P. Ruff, M. Rother,
C. W. Johnson, A. Zhang, J. L. Gansert, J. Douillard
258